SEARCH:   Advanced

Blood, 15 February 2007, Vol. 109, No. 4, pp. 1408-1413. Prepublished online as a Blood First Edition Paper on October 24, 2006; DOI 10.1182/blood-2006-03-011908. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-03-011908v1 109/4/1408    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by de Labarthe, A. Articles by Dombret, H. Search for Related Content PubMed PubMed Citation Articles by de Labarthe, A. Articles by Dombret, H. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study Adrienne de Labarthe1, Philippe Rousselot2, Françoise Huguet-Rigal3, Eric Delabesse4, Francis Witz5, Sébastien Maury6, Delphine Réa1, Jean-Michel Cayuela1, Marie-Christine Vekemans7, Oumedaly Reman8, Agnès Buzyn4, Arnaud Pigneux9, Martine Escoffre10, Yves Chalandon11, Elizabeth MacIntyre4, Véronique Lhéritier12, Jean-Paul Vernant13, Xavier Thomas12, Norbert Ifrah14, Hervé Dombret, for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)1 1 Department of Hematology, Hôpital Saint-Louis, Paris, France; 2 Department of Hematology, Hôpital André Mignot, Versailles, France; 3 Department of Hematology, Hôpital Purpan, Toulouse, France; 4 Department of Hematology, Hôpital Necker, Paris, France; 5 Department of Hematology, Hôpital de Brabois, Nancy, France; 6 Department of Hematology, Hôpital Henri Mondor, Créteil, France; 7 Department of Hematology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; 8 Department of Hematology, Centre Hospitalier Universitaire, Caen, France; 9 Department of Hematology, Hôpital Haut-Lévèque, Pessac, France; 10 Department of Hematology, Centre Hospitalier Universitaire, Rennes, France; 11 Department of Hematology, Hôpital Universitaire, Genève, Switzerland; 12 Department of Hematology, Hôpital Edouard Herriot, Lyon, France; 13 Department of Hematology, Hôpital Pitié-Salpêtrière, Paris, France; 14 Department of Hematology, Centre Hospitalier Universitaire, Angers, France The combination of imatinib with chemotherapy has been recently reported as very promising in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL). Imatinib was then continuously administered until stem cell transplantation (SCT). Overall, complete remission (CR) and BCR-ABL real-time quantitative polymerase chain reaction (RQ-PCR) negativity rates were 96% and 29%, respectively. All of the 22 CR patients (100%) with a donor actually received allogeneic SCT in first CR. At 18 months, the estimated cumulative incidence of relapse, disease-free survival, and overall survival were 30%, 51%, and 65%, respectively. These 3 end points compared very favorably with results obtained in the pre-imatinib LALA-94 trial. This study confirms the value of the combined approach and encourages prospective trials to define the optimal chemotherapy that has to be combined with imatinib and to carefully reevaluate the place of allogeneic SCT in this new context. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Huguet, T. Leguay, E. Raffoux, X. Thomas, K. Beldjord, E. Delabesse, P. Chevallier, A. Buzyn, A. Delannoy, Y. Chalandon, et al. Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study J. Clin. Oncol., February 20, 2009; 27(6): 911 - 918. [Abstract] [Full Text] [PDF] S. M. O'Brien, D. A. Thomas, and S. Faderl A La Carte Therapy of Specific Acute Lymphocytic Leukemia Subsets ASCO Educational Book, January 1, 2009; 2009(1): 365 - 370. [Abstract] [Full Text] [PDF] R.T. Williams and C.J. Sherr The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias Cold Spring Harb Symp Quant Biol, November 26, 2008; (2008) sqb.2008.73.039v2. [Abstract] [PDF] R. J. Schilder, M. W. Sill, R. B. Lee, T. J. Shaw, M. K. Senterman, A. J. Klein-Szanto, Z. Miner, and B. C. Vanderhyden Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., July 10, 2008; 26(20): 3418 - 3425. [Abstract] [Full Text] [PDF] J. Kanter, S. Y. Khan, M. Kelher, L. Gore, and C. C. Silliman Oncogenic and Angiogenic Growth Factors Accumulate during Routine Storage of Apheresis Platelet Concentrates Clin. Cancer Res., June 15, 2008; 14(12): 3942 - 3947. [Abstract] [Full Text] [PDF] C. Oudot, M.-F. Auclerc, V. Levy, R. Porcher, C. Piguet, Y. Perel, V. Gandemer, M. Debre, C. Vermylen, B. Pautard, et al. Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study J. Clin. Oncol., March 20, 2008; 26(9): 1496 - 1503. [Abstract] [Full Text] [PDF] M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, K. Nishii, Y. Ueda, M. Takeuchi, S. Miyawaki, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy Haematologica, February 1, 2008; 93(2): 287 - 290. [Abstract] [Full Text] [PDF] M. Wetzler Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: On Target to Improve Outcome ASCO Educational Book, January 1, 2008; 2008(1): 275 - 279. [Abstract] [Full Text] [PDF] J. L. Fuster, M. Bermudez, A. Galera, M. E. Llinares, D. Calle, and F. J. Ortuno Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia Haematologica, December 1, 2007; 92(12): 1723 - 1724. [Abstract] [Full Text] [PDF] J. M. Rowe and A. H. Goldstone How I treat acute lymphocytic leukemia in adults Blood, October 1, 2007; 110(7): 2268 - 2275. [Abstract] [Full Text] [PDF] R. T. Williams, W. den Besten, and C. J. Sherr Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia Genes & Dev., September 15, 2007; 21(18): 2283 - 2287. [Abstract] [Full Text] [PDF] D. A. Thomas Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges Hematology, January 1, 2007; 2007(1): 435 - 443. [Abstract] [Full Text] [PDF] H. M. Lazarus and S. Luger Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion Hematology, January 1, 2007; 2007(1): 444 - 452. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020